Drug Combo Works Better for RA

MAY 01, 2004

In the first study of its kind, researchers investigated whether giving a combination of drugs at the onset of rheumatoid arthritis (RA) would be better than using 1 alone. Traditionally, methotrexate has been used to treat RA. Yet, 2 out of 3 patients do not respond well to it, the researchers reported.

For the study, researchers administered methotrexate or etanercept (Enbrel, Wyeth Pharmaceuticals) or both drugs to 682 patients. Enbrel is part of a class of medicines that target an inflammation-causing protein called tumor necrosis factor. These drugs have helped individuals who have not responded to methotrexate.

The researchers analyzed the data and found that, after 1 year of treatment, 35% of the patients in the combination group were in remission, compared with 13% of those on methotrexate alone and 16% of those on Enbrel alone. Also, no additional deterioration of joints was noted in 80% of the patients on combination treatment, compared with 68% of those on methotrexate and 57% of those on Enbrel alone. (These findings were published recently in The Lancet.)



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.